相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)
Christopher M. Booth et al.
EUROPEAN JOURNAL OF CANCER (2008)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
Federica Grosso et al.
LANCET ONCOLOGY (2007)
Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group
A. Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
We should desist using RECIST, at least in GIST
Robert S. Benjamin et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
Haesun Choi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group
Jean-Yves Blay et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gastrointestinal stromal tumors treated with imatinib:: Monitoring response with contrast-enhanced sonography
Nathalie Lassau et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2006)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
RECIST revisited: A review of validation studies on tumour assessment
P. Therasse et al.
EUROPEAN JOURNAL OF CANCER (2006)
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
JR Zalcberg et al.
EUROPEAN JOURNAL OF CANCER (2005)
RECIST vs. WHO:: Prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma
P Therasse et al.
EUROPEAN JOURNAL OF CANCER (2005)
Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients
D Vanel et al.
EUROPEAN JOURNAL OF RADIOLOGY (2005)
Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
A Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET
PL Jager et al.
NUCLEAR MEDICINE COMMUNICATIONS (2004)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings
H Choi et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2004)
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®)
S Stroobants et al.
EUROPEAN JOURNAL OF CANCER (2003)
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy
JY Blay et al.
EUROPEAN JOURNAL OF CANCER (2003)
Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate)
MYM Chen et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2002)
Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs)
AD Van den Abbeele et al.
EUROPEAN JOURNAL OF CANCER (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
M Van Glabbeke et al.
EUROPEAN JOURNAL OF CANCER (2002)
Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study
AT van Oosterom et al.
LANCET (2001)
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
A Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)